Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma. - Scholte M; Fernández Coves A; Yang H; Armstrong N; McDermott K; Tian X; Stirk L; Wolff R; Joore MA; Grimm SE (PharmacoEconomics, 2026)